The original success of the copyright undeniably transformed the drug landscape, but investing in companies heavily reliant on generic versions presents a uncertain picture. Despite early returns were impressive, the end of patents and the appearance of cheaper alternatives have weakened sales. Therefore, a thorough assessment of ongoing financial